[go: up one dir, main page]

IN2012DN00999A - - Google Patents

Info

Publication number
IN2012DN00999A
IN2012DN00999A IN999DEN2012A IN2012DN00999A IN 2012DN00999 A IN2012DN00999 A IN 2012DN00999A IN 999DEN2012 A IN999DEN2012 A IN 999DEN2012A IN 2012DN00999 A IN2012DN00999 A IN 2012DN00999A
Authority
IN
India
Prior art keywords
solvates
useful
formula
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
Inventor
James A Henderson
John Maxwell
Louis Vaillancourt
Mark Morris
Jr Ronald Grey
Simon Giroux
Laval Chan Chun Kong
Sanjoy Kumar Das
Bingcan Liu
Carl Poisson
Caroline Cadilhac
Monica Bubenik
T Jagadeeswar Reddy
Guy Falardeau
Constantin Yannopoulos
Jian Wang
Oswy Z Pereira
Youssef L Bennani
Albert C Pierce
Govinda Rao Bhisetti
Kevin M Cottrell
Valerie Marone
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IN2012DN00999A publication Critical patent/IN2012DN00999A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Compounds represented by formula (I) or pharmaceutically acceptable salts and solvates thereof, where A, B, B', X, Y, Rl', R2', R3', R5, R5', R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.
IN999DEN2012 2009-07-16 2010-07-16 IN2012DN00999A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22615209P 2009-07-16 2009-07-16
US31701710P 2010-03-24 2010-03-24
PCT/US2010/042340 WO2011009084A2 (en) 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of flavivirus infections

Publications (1)

Publication Number Publication Date
IN2012DN00999A true IN2012DN00999A (en) 2015-04-10

Family

ID=43385139

Family Applications (1)

Application Number Title Priority Date Filing Date
IN999DEN2012 IN2012DN00999A (en) 2009-07-16 2010-07-16

Country Status (10)

Country Link
US (3) US8354419B2 (en)
EP (1) EP2454254A2 (en)
JP (1) JP2012533569A (en)
CN (1) CN102656160A (en)
AU (1) AU2010274001A1 (en)
CA (1) CA2767887A1 (en)
IL (1) IL217503A0 (en)
IN (1) IN2012DN00999A (en)
MX (1) MX2012000695A (en)
WO (1) WO2011009084A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
MX2011006332A (en) 2008-12-23 2011-06-27 Abbott Lab Anti-viral compounds.
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
BRPI1010795B1 (en) 2009-05-13 2018-12-11 Gilead Pharmasset Llc antiviral compounds, their use and pharmaceutical composition comprising the same
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010138790A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
PE20110679A1 (en) 2009-06-11 2011-10-20 Abbvie Bahamas Ltd (4-TERT-BUTYLPHENYL) PYRROLIDIN-2,5-DIPHENYL DERIVED AS HCV INHIBITORS
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102656160A (en) * 2009-07-16 2012-09-05 顶点制药公司 Benzimidazole analogues for use in the treatment or prevention of flavivirus infections
BR112012004969A2 (en) * 2009-09-03 2019-09-24 Tibotec Pharm Ltd bis-benzimidazole derivatives
CN102480971B (en) 2009-09-04 2014-11-26 杨森制药公司 Chemical compounds
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2554087C2 (en) * 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-condensed arylene or heteroarylene hepatitis c virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20130244A1 (en) 2010-01-25 2013-03-10 Enanta Pharm Inc HEPATITIS C VIRUS INHIBITORS
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
BR112012022311A2 (en) * 2010-03-04 2016-08-23 Enanta Pharm Inc combination pharmaceutical agents as inhibitors of hcv replication.
MX2012010918A (en) 2010-03-24 2013-01-18 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections.
EP2550262A1 (en) * 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc Hepatitis c virus inhibitors
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc Hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20150158909A1 (en) * 2010-12-15 2015-06-11 Abbevie Inc. Anti-viral compounds
CN103384664A (en) * 2010-12-16 2013-11-06 Abbvie公司 Anti-viral compounds
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (en) 2011-05-18 2014-03-26 埃南塔制药公司 Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
EP2714693A4 (en) * 2011-05-26 2014-12-10 Abbvie Inc Anti-viral compounds
US20150126747A1 (en) * 2011-05-26 2015-05-07 Abbvie Inc. Anti-viral compounds
CA2841095A1 (en) * 2011-07-09 2013-01-17 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JP6170944B2 (en) 2011-12-28 2017-07-26 ヤンセン・サイエンシズ・アイルランド・ユーシー Hetero-bicyclic derivatives as HCV inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014018979A1 (en) 2012-07-27 2014-01-30 The Broad Institute, Inc. Inhibitors of histone deacetylase
TWI610916B (en) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof
CN103848818B (en) 2012-11-29 2017-03-15 广东东阳光药业有限公司 Simultaneously cycle compound, pharmaceutical composition and their applications in medicine as hepatitis c inhibitor
CN103848821B (en) 2012-11-29 2016-10-12 广东东阳光药业有限公司 Spiro-compound, pharmaceutical composition and their purposes as hepatitis c inhibitor
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (en) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Combinations comprising biphenyl derivatives for use in the treatment of HCV
JP2016529293A (en) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー Combination preparation of two antiviral compounds
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104803989B (en) 2014-01-23 2017-12-22 广东东阳光药业有限公司 Application as the endocyclic compound of hepatitis c inhibitor and its in medicine
JP2016079168A (en) 2014-10-17 2016-05-16 塩野義製薬株式会社 9 membered condensed-ring derivative
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
US11096927B2 (en) 2018-12-19 2021-08-24 Florida State University Research Foundation, Inc. Anti-flavivirus compounds and methods of use
US20230312542A1 (en) * 2020-03-31 2023-10-05 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
CN117321059A (en) 2021-05-21 2023-12-29 吉利德科学公司 Tetracyclic compounds for the treatment of Zika virus infection
CN117460734A (en) 2021-05-21 2024-01-26 吉利德科学公司 Pentacyclic derivatives as Zika virus inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014313A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
PL1718608T3 (en) 2004-02-20 2013-11-29 Boehringer Ingelheim Int Viral polymerase inhibitors
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
PT2250163E (en) 2008-02-12 2012-06-01 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DK2242752T3 (en) 2008-02-13 2012-11-19 Bristol Myers Squibb Co Imidazolyl-biphenylimidazoles as hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5100595B2 (en) 2008-09-30 2012-12-19 シャープ株式会社 AV equipment, server, AV equipment operating system, and AV equipment operating program
JP5268532B2 (en) 2008-09-30 2013-08-21 株式会社日立ハイテクノロジーズ Sample measuring method and measuring apparatus
JP5225240B2 (en) 2008-10-01 2013-07-03 住友ゴム工業株式会社 Rubber composition for tire and tire
AU2009322400A1 (en) 2008-12-03 2011-06-30 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
JP5762971B2 (en) 2008-12-03 2015-08-12 プレシディオ ファーマシューティカルズ インコーポレイテッド Inhibitor of HCVNS5A
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (en) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Hepatitis c virus inhibitors
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CA2753382C (en) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
CN109651342A (en) 2009-03-27 2019-04-19 默沙东公司 The inhibitor of hepatitis c viral replication
MX2011010132A (en) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c.
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI476190B (en) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Hepatitis c virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
BRPI1016172A2 (en) 2009-04-24 2016-04-19 Tibotec Pharm Ltd diaryl ethers
EP2430015B1 (en) 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Fused tricyclic compounds useful for the treatment of viral diseases
BRPI1010795B1 (en) 2009-05-13 2018-12-11 Gilead Pharmasset Llc antiviral compounds, their use and pharmaceutical composition comprising the same
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
PE20110679A1 (en) 2009-06-11 2011-10-20 Abbvie Bahamas Ltd (4-TERT-BUTYLPHENYL) PYRROLIDIN-2,5-DIPHENYL DERIVED AS HCV INHIBITORS
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
CN102656160A (en) * 2009-07-16 2012-09-05 顶点制药公司 Benzimidazole analogues for use in the treatment or prevention of flavivirus infections
CN102480971B (en) 2009-09-04 2014-11-26 杨森制药公司 Chemical compounds
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2554087C2 (en) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-condensed arylene or heteroarylene hepatitis c virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
PE20130244A1 (en) 2010-01-25 2013-03-10 Enanta Pharm Inc HEPATITIS C VIRUS INHIBITORS
BR112012022311A2 (en) 2010-03-04 2016-08-23 Enanta Pharm Inc combination pharmaceutical agents as inhibitors of hcv replication.
CN102918049A (en) 2010-03-09 2013-02-06 默沙东公司 Fused tricyclic silyl compounds and methods for their use in treating viral diseases
EP2550262A1 (en) * 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc Hepatitis c virus inhibitors
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
CA2800530A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc Hepatitis c virus inhibitors
US20130310427A1 (en) 2010-06-09 2013-11-21 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
AU2010358561B2 (en) 2010-08-04 2016-06-02 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
EP2619195A1 (en) 2010-09-24 2013-07-31 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
MX2013003631A (en) 2010-09-29 2013-10-01 Merck Sharp & Dohme Tetracyclic indole derivatives for treating hepatitis c virus infection.
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION
US20130302282A1 (en) 2010-10-26 2013-11-14 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
LT2714036T (en) 2011-05-27 2016-10-10 Achillion Pharmaceuticals, Inc. Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections

Also Published As

Publication number Publication date
MX2012000695A (en) 2012-06-12
US8354419B2 (en) 2013-01-15
CN102656160A (en) 2012-09-05
US20140243257A1 (en) 2014-08-28
AU2010274001A1 (en) 2012-02-23
US20130157997A1 (en) 2013-06-20
WO2011009084A3 (en) 2011-04-28
CA2767887A1 (en) 2011-01-20
US20110172238A1 (en) 2011-07-14
JP2012533569A (en) 2012-12-27
US8765731B2 (en) 2014-07-01
WO2011009084A2 (en) 2011-01-20
EP2454254A2 (en) 2012-05-23
IL217503A0 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
IN2012DN00999A (en)
MX2012007420A (en) Analogues for the treatment or prevention of flavivirus infections.
MX2012010918A (en) Analogues for the treatment or prevention of flavivirus infections.
SG178952A1 (en) Chemical compounds
IN2012DN01855A (en)
MX2012000959A (en) Inhibitors of flaviviridae viruses.
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2011011136A (en) Diaryl ethers.
MX2014001595A (en) Indazole compounds, compositions and methods of use.
MX2009010642A (en) Oxazolidinone antibiotics.
MX2013006475A (en) Macrocyclic inhibitors of flaviviridae viruses.
MX2010004623A (en) Heterocyclic antiviral compounds.
MX2009009473A (en) Compounds for the treatment of hepatitis c.
MX2012003170A (en) Heterocyclic antiviral compounds.
TNSN08407A1 (en) Organic compounds
TN2010000212A1 (en) Inhibitors of human immunodeficiency virus replication
PH12012501546A1 (en) Substituted pyrrolidine-2-carboxamides
MX2012006026A (en) 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections.
MY151986A (en) Adamantyl diamide derivatives and uses of same
NZ600817A (en) Inhibitors of flaviviridae viruses
MX2010002461A (en) (carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament.
MX2009012222A (en) Dihydroquinone and dihydronaphthridine inhibitors of jnk.
MX2012008221A (en) Inhibitors of flaviviridae viruses.
EA201270275A1 (en) CRYSTALLINE PYRIDAZINE CONNECTION